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Bacteria in the respiratory tract and wheeze in children
Colonisation is more common in symptomatic children, but causation is not 
established
In the linked cohort study Bisgaard and colleagues assess 
the association between wheezy symptoms in young 
children and the presence of bacteria in the airway.1 
Lower respiratory tract illnesses presenting with cough, 
shortness of breath, or wheeze are common in preschool 
years.2 It has been proposed that, for the management 
of preschool wheeze, a distinction is made between epi-
sodic and multiple trigger wheeze.3 Episodic wheeze is 
defined as wheeze in discrete episodes of up to two to 
four weeks’ duration, usually triggered by a viral infec-
tion, and with the child being well in between. In multi-
trigger wheeze, the child has distinct episodes of wheeze 
but also has intermittent symptoms, such as cough and 
wheeze at night or in response to exercise, crying, laugh-
ter, mist, and cold air, between these episodes. Viral 
infections are again the most common triggers, but multi-
trigger wheeze is often associated with allergic features, 
and many children with preschool multi-trigger wheeze 
progress to chronic asthma. Current guidelines recom-
mend the use of bronchodilators for wheezing episodes.3 
Children with multi-trigger wheeze may also benefit from 
inhaled  corticosteroids and leukotriene receptor agonists. 
 Antibiotics have not been recommended for the treatment 
of preschool episodic wheeze or multi-trigger wheeze.
This approach is contested by Bisgaard and col-
leagues’ study.1 The authors included 361 infants born 
to asthmatic mothers who were followed until the age of 
3 years. They confirmed a positive association between 
viruses and preschool wheeze (odds ratio 2.8, 95% con-
fidence interval 1.7 to 4.4) and also found a significant 
association between bacteria and preschool wheeze 
(2.9, 1.9 to 4.3), which was independent of viral detec-
tion. For all episodes of lower respiratory tract illness 
the children were seen in the study centre and the condi-
tion was classified as wheeze or “clinical pneumonia,” 
which was defined as tachypnoea, fever, and  crepitations 
over the lungs without wheeze. In addition, children 
were scheduled to be seen once a year. At each visit 
 hypopharyngeal aspirates were taken for bacterial culture 
and  rhinopharyngeal aspirates were taken for polymerase 
chain reaction analysis of viruses and atypical bacteria.
Viruses were detected in 40% of asymptomatic  children, 
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in 65% of wheezy episodes, and in 70% of episodes with 
clinical pneumonia. Bacteria were detected in 62% of 
asymptomatic children, 86% of wheezy children, and 
93% of children with clinical pneumonia. Most com-
monly Streptococcus pneumoniae was identified, followed 
by Haemophilus influenzae and Moraxella catarrhalis. 
Atypical bacteria were detected in fewer than 2% of the 
children. Thus in both conditions—wheezing and non-
wheezing lower respiratory tract illnesses—viruses and 
bacteria were detected significantly more in affected chil-
dren than in asymptomatic children. The positive associa-
tion with the detection of bacteria remained significant 
after adjusting for the detection of viruses. The authors 
suggest that this might have important effects on the treat-
ment of preschool wheeze if the role of bacteria can be 
confirmed.
The high bacterial detection rate reported in asymp-
tomatic children in this study casts some doubt over a 
causative role for bacteria. The findings confirm a previ-
ous study investigating bacterial colonisation of new-
borns by conventional culture methods.4 All nose and 
throat smears from 3 day old babies produced positive 
cultures. Another study using culture independent molec-
ular methods for the detection of bacteria has shown that 
the lower respiratory tract—which was thought to be ster-
ile—is highly colonised by bacteria. Bronchoscopy was 
performed on 24 adults and 20 children and found that 
every cm2 contained a mean of 2000 bacterial genomes, 
including H influenzae and S pneumoniae.5 Thus, positive 
bacterial cultures may merely reflect colonisation of the 
upper and lower respiratory tract rather than indicating 
that bacteria are the cause of the infection. Viral infections 
may indirectly facilitate bacterial growth, thereby increas-
ing detection rates in acute episodes.
Ultimately, only controlled clinical trials with antibiotic 
treatment can resolve this debate, as the authors rightly 
acknowledge. Besides the studies discussed by Bisgaard 
and colleagues,6  7 the findings of two other randomised 
controlled trials might be more informative. These trials 
investigated the effect of adding an aminopenicillin to 
standard care of acute exacerbations of asthma in chil-
dren8 and adults,9 and they found that antibiotics had 
no benefit. These findings are particularly interesting 
because aminopenicillins are generally effective against 
H  influenzae and S pneumoniae—the most commonly 
detected bacteria in this study. However, these trials are 
limited by the small number of people included (44 and 
71). Unless well designed and high powered clinical tri-
als unambiguously show a benefit of antibiotic treatment 
there is no need to revise the management guidelines for 
preschool wheeze.
The findings are nonetheless interesting because they 
emphasise the need for a better understanding of the 
role of bacteria in the development of asthma and acute 
exacerbations of the disease. The advent of culture inde-
pendent molecular methods that can detect much higher 
numbers of known and unknown bacteria will allow a 
better understanding of the role of bacteria in the coloni-
sation of mucosal surfaces in the airways, their interac-
tion with local host immune responses, and eventually 
their contribution to disease onset and progression.
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